SMO inhibition with cyclopamine, a steroidal alkaloid isolated from the Veratrum californicum plant, has been demonstrated in human OSA cell lines to result in a dose- and time-dependent decrease in metabolic activity [27, 29]. The gene discussed is SMO; the disease is obstructive sleep apnea syndrome.